Effect of periodontitis on overt nephropathy and end-stage renal disease in type 2 diabetes

被引:198
|
作者
Shultis, Wendy A.
Weil, E. Jennifer
Looker, Helen C.
Curtis, Jeffrey M.
Shlossman, Marc
Genco, Robert J.
Knowler, William C.
Nelson, Robert G.
机构
[1] Natl Inst Hlth, Diabet Epidemiol & Clin Res Sect, Phoenix Epidemiol & Clin Res Branch, NIDDKD, Phoenix, AZ 85014 USA
[2] SUNY Buffalo, Dept Oral Biol, Buffalo, NY 14260 USA
[3] Arizona Sch Dent & Oral Hlth, Mesa, AZ USA
关键词
D O I
10.2337/dc06-1184
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - The purpose of this study was to investigate the effect of periodontitis on development of overt nephropathy, defined as macroalbuminuria, and end-stage renal disease (ESRD) in type 2 diabetes. RESEARCH DESIGN AND METHODS - individuals residing in the Gila River Indian Community aged >= 25 years with type 2 diabetes, one or more periodontal examination, estimated glomerular filtration rate >= 60 ml/min per 1.73 m(2), and no macroalbuminuria (urinary albumin-to-creatinine ratio >= 300 mg/g) were identified. Periodontitis was classified as none/mild, moderate, severe, or edentulous using number of teeth and alveolar bone score. Subjects were followed to development of macroalbuminuria or ESRD, defined as onset of renal replacement therapy or death attributed to diabetic nephropathy. RESULTS - Of the 529 individuals, 107 (20%) had none/mild periodontitis, 200 (38%) had moderate periodontitis, 117 (22%) had severe periodontitis, and 105 (20%) were edentulous at baseline. During follow-up of up to 22 years, 193 individuals developed macroalbuminuria and 68 developed ESRD. Age- and sex-adjusted incidence of macroalbuminuria and ESRD increased with severity of periodontitis. After adjustment for age, sex, diabetes duration, BMI, and smoking in a proportional hazards model, the incidences of macroalbuminuria were 2.0, 2.1, and 2.6 Limes as high in individuals With moderate or severe periodontitis or those Who were edentulous, respectively, compared with those with none/mild periodontitis (P = 0.01). Incidences of ESRD in individuals with moderate or severe periodontitis or in those who were edentulous were 2.3, 3.5, and 4.9 times as high, respectively, compared with those with none/mild periodontitis (P 0.02). CONCLUSIONS - Periodontitis predicts development of overt nephropathy and ESRD in individuals with type 2 diabetes. Whether treatment of periodontitis will reduce the risk of diabetic kidney disease remains to be determined.
引用
收藏
页码:306 / 311
页数:6
相关论文
共 50 条
  • [1] Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy
    Mohanram, A
    Zhang, Z
    Shahinfar, S
    Keane, WF
    Brenner, BM
    Toto, RD
    KIDNEY INTERNATIONAL, 2004, 66 (03) : 1131 - 1138
  • [2] Worsening anemia predicts end-stage renal disease (ESRD) in patients with type 2 diabetes and nephropathy
    Mohanram, A
    Zhang, ZX
    Shahinfar, S
    Keane, W
    Brenner, BM
    Toto, RD
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 43 (04) : A33 - A33
  • [3] The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study
    Keane, WF
    Brenner, BM
    de Zeeuw, D
    Grunfeld, JP
    McGill, J
    Mitch, WE
    Ribeiro, AB
    Shahinfar, S
    Simpson, RL
    Snapinn, SM
    Toto, R
    KIDNEY INTERNATIONAL, 2003, 63 (04) : 1499 - 1507
  • [4] The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy
    Carides, George W.
    Shahinfar, Shahnaz
    Dasbach, Erik J.
    Keane, William F.
    Gerth, William C.
    Alexander, Charles M.
    Herman, William H.
    Brenner, Barry M.
    PHARMACOECONOMICS, 2006, 24 (06) : 549 - 558
  • [5] The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy
    George W. Carides
    Shahnaz Shahinfar
    Erik J. Dasbach
    William F. Keane
    William C. Gerth
    Charles M. Alexander
    William H. Herman
    Barry M. Brenner
    PharmacoEconomics, 2006, 24 : 549 - 558
  • [6] Renal Function Decline, End-Stage Renal Disease, and Death in Diabetic Nephropathy: Concordant Risks in Type 1 and Type 2 Diabetes
    Hadjadj, Samy
    Cariou, Bertrand
    Fumeron, Frederic
    Gand, Elise
    Charpentier, Guillaume
    Roussel, Ronan
    Kasmi, Ahmed-Amine
    Gautier, Jean Francois
    Mohammedi, Kamel
    Gourdy, Pierre
    Saulnier, Pierre Jean
    Marre, Michel
    DIABETES, 2015, 64 : A147 - A147
  • [7] Hypomagnesemia in Type 2 Diabetic Nephropathy A novel predictor of end-stage renal disease
    Sakaguchi, Yusuke
    Shoji, Tatsuya
    Hayashi, Terumasa
    Suzuki, Akira
    Shimizu, Morihiro
    Mitsumoto, Kensuke
    Kawabata, Hiroaki
    Niihata, Kakuya
    Okada, Noriyuki
    Isaka, Yoshitaka
    Rakugi, Hiromi
    Tsubakihara, Yoshiharu
    DIABETES CARE, 2012, 35 (07) : 1591 - 1597
  • [8] Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes
    Krolewski, Andrzej S.
    Skupien, Jan
    Rossing, Peter
    Warram, James H.
    KIDNEY INTERNATIONAL, 2017, 91 (06) : 1300 - 1311
  • [9] End-stage renal disease in patients with type 1 diabetes
    Lofthouse M.
    Nature Clinical Practice Endocrinology & Metabolism, 2006, 2 (1): : 4 - 4
  • [10] Prevention of end-stage renal disease due to type 2 diabetes.
    Hostetter, TH
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12): : 910 - 912